XR Technology Secures Strategic Investment from HT GenScript to Accelerate Automation from Life Science Labs to Production

Recently, Xrazor Technology (XR TECHNOLOGY), a leading domestic provider of high-end life science automation platforms, announced the successful completion of its Series A+ strategic financing round, which was jointly participated in by Huatai GenScript and Shunwei Capital.

Xrazor Technology is dedicated to providing premium products and one-stop comprehensive solutions for the life sciences sector. Leveraging its robust product portfolio and strong end-to-end delivery capabilities, the company continues to drive industry innovation. With this round of financing, Xrazor Technology will increase R&D investment and expand its commercial footprint, thereby enhancing its capacity to serve cutting-edge fields such as drug discovery, synthetic biology, and diagnostic testing.As a professional value provider in the life sciences sector, Xrazor Technology has successfully expanded into new fields of laboratory automation for chemistry and new energy based on its standardized technology platform, delivering numerous projects.

Xrazor Technology has built robust product capabilities, ensuring efficient delivery and reliable quality, by leveraging its core team’s extensive R&D experience in robotics gained at multinational corporations and its stringent quality control system. The company employs a specialized biochemical team to provide customers with top-tier services, including technical support, design delivery, and after-sales maintenance.Service Scope Covers Gene and Cell Technologies, Omics Analysis, Molecular Biology, Synthetic Biology, Pharmaceutical R&D and Manufacturing, and Drug GMP ComplianceWaitNumerous Fields.

Xrazor Technology has, through years of iterative upgrades, developed a sophisticated fluid control technology platform that ensures higher precision and greater robustness in liquid handling and solid-powder dispensing. Products and solutions based on this platform have been thoroughly validated and recognized by leading enterprises across multiple industries, achieving standardized repeat purchases and deliveries in recent years. Since its inception, the company has remained committed to improving labor productivity and emphasizing refined daily management, demonstrating exceptional resource allocation efficiency. Meanwhile, upholding its corporate vision of growing together with customers, Xrazor Technology continues to drive the advancement of the life sciences industry.

GenScript Biotech Corporation (HK.1548) is a global leader in life science R&D and manufacturing services. Built on a solid foundation of DNA synthesis technology, GenScript has established four major business units: Life Science Services & Products, Biologics Contract Development and Manufacturing Organization (CDMO), Industrial Synthetic Biology Products, and a comprehensive global cell therapy company. Since its inception in 2002, GenScript has partnered with collaborators to accelerate scientific discoveries and therapeutic breakthroughs. Its operations span more than 100 countries and regions worldwide, serving over 200,000 customers with high-quality services and products. GenScript currently employs more than 7,200 people globally. As of June 30, 2024, GenScript’s services and products have been cited in over 100,000 peer-reviewed academic journal articles worldwide. Upholding its corporate mission of “Making Humans and Nature Healthier through Biotechnology,” GenScript is committed to becoming the “Most Trusted Biotechnology Company” globally.

Huatai Zijin is a wholly-owned subsidiary of Huatai Securities (601688.SH) engaged in private equity investment. Leveraging the full business chain advantages of Huatai Securities and adhering to the investment philosophy of “growing together with entrepreneurs,” the company provides comprehensive capital services to partners by utilizing its abundant financial and industrial resources. With a registered capital of RMB 6 billion and assets under management exceeding RMB 60 billion, Huatai Zijin manages multiple funds, including PE, M&A, FOF, and industry-specific funds. Committed to its industry positioning, Huatai Zijin conducts in-depth research and focuses on strategic emerging sectors such as healthcare, TMT, and advanced manufacturing, accumulating extensive industry experience and resources. Its healthcare investment portfolio includes Mindray Medical (300760), WuXi AppTec (603259.SH/2359.HK), RemeGen (09995.HK), Getein Biotech (603387), Borui Medicine (688166), Addex Therapeutics China (688488), BioGerm (688399), Shuyu Pingmin Pharmacy (301017), Lifetech Scientific (688389), HeartCare Medical (2160.HK), Vazyme Biotech (688105), Geneseeq, Yikelai, Sepax Technologies, and XinQiang Medical.

Shunwei Capital was founded in 2011 by Mr. Lei Jun and Mr. Xu Dalai. It currently manages dual-currency funds in USD and RMB with assets under management exceeding $6 billion. Its limited partners primarily consist of global top-tier institutional investors, including sovereign wealth funds, family offices, funds of funds, and university endowments. Shunwei Capital focuses on key sectors such as mobile internet, Internet Plus, smart hardware, intelligent manufacturing, deep tech, consumer goods, enterprise services, and the electric vehicle ecosystem. The firm has invested in over 600 outstanding companies domestically and internationally, including Xiaomi Corporation, Ninebot, Agora, iQIYI, NIO, ShareChat, and Meesho. Through investing in visionary enterprises from the early to growth stages, Shunwei Capital aims to make life better.

Xrazor Technology, adhering to the philosophy of "technology first, efficiency foremost," has been deeply engaged in the life sciences automation industry since its establishment in 2020. Leveraging advanced robotics and domestically leading fluidic control technologies, the company provides high-end intelligent platforms for drug research and production, synthetic biology, and diagnostic testing, helping clients increase experimental throughput, optimize experimental quality, and enhance R&D and production efficiency. With a 5,000-square-meter R&D and production base across multiple locations in Shanghai and Jiangsu Province, Xrazor Technology offers comprehensive services ranging from system solutions and product delivery to after-sales support. Since its inception, the company has secured hundreds of millions of yuan in financing from top-tier investment institutions and has been honored with numerous titles, including National High-Tech Enterprise, Shanghai "Specialized, Refined, Differential, and Innovative" SME, Innovative SME, Growth-Oriented Tech Enterprise, and Key Talent Introduction Institution.